Artiva Biotherapeutics, Inc.’s (NASDAQ:ARTV) Lock-Up Period To End on January 15th

Artiva Biotherapeutics’ (NASDAQ:ARTV) lock-up period is set to expire on Wednesday, January 15th. Artiva Biotherapeutics had issued 13,920,000 shares in its IPO on July 19th. The total size of the offering was $167,040,000 based on an initial share price of $12.00. After the expiration of Artiva Biotherapeutics’ lock-up period, major shareholders and company insiders will be able to sell their shares of the company.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on ARTV shares. Needham & Company LLC reissued a “buy” rating and set a $23.00 price objective on shares of Artiva Biotherapeutics in a report on Wednesday, November 13th. HC Wainwright began coverage on Artiva Biotherapeutics in a research note on Monday, December 30th. They set a “buy” rating and a $20.00 price target on the stock. Six analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and an average price target of $21.00.

Artiva Biotherapeutics Trading Down 3.0 %

Shares of ARTV opened at $10.26 on Friday. Artiva Biotherapeutics has a 52-week low of $9.68 and a 52-week high of $17.31. The firm has a 50 day simple moving average of $11.37.

Artiva Biotherapeutics (NASDAQ:ARTV) last issued its earnings results on Tuesday, November 12th. The company reported ($0.92) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.24). Equities analysts predict that Artiva Biotherapeutics will post -4.68 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. RA Capital Management L.P. bought a new position in Artiva Biotherapeutics in the 3rd quarter valued at about $152,234,000. Franklin Resources Inc. bought a new position in shares of Artiva Biotherapeutics in the third quarter valued at approximately $7,435,000. Geode Capital Management LLC purchased a new position in shares of Artiva Biotherapeutics during the third quarter valued at approximately $4,774,000. Samsara BioCapital LLC bought a new stake in Artiva Biotherapeutics during the third quarter worth $4,506,000. Finally, Wellington Management Group LLP purchased a new stake in Artiva Biotherapeutics in the 3rd quarter valued at $2,912,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.